18-Nov-2026 12:58:34

WANBURYGeneral news

WANBURY Q2 FY27: EXPECTS STRONGER H2; FULL MARGIN RECOVERY & NEW API LAUNCHES TO DRIVE GROWTH

• H2 FY27 Outlook: Management expects stronger revenue and profitability, supported by margin recovery and commercialisation of new API products • Margin Recovery: EBITDA margin improved to 14.3% from 10.0% in Q1 FY27; expects full recovery as raw material cost pass-through completes • Raw Material Costs: Substantial portion of elevated solvent and crude-linked input costs already passed on to customers, with remaining increases expected to be passed on in Q3 FY27 • New API Launches: Expects progress towards the end of FY27, with revenue contribution anticipated in FY28 • USFDA Approvals: Received nine No DMF Deficiency letters for Metformin HCl, along with similar letters for Paroxetine HCl and Diphenhydramine HCl • European Market: Received CEP certification from EDQM for Rivaroxaban API, supporting opportunities in European markets • Australian Regulatory Approval: Tanuku manufacturing facility received TGA GMP compliance certification • Export Expansion: Secured new Metformin business in Saudi Arabia and Mexico • Dermatology Expansion: Entered paediatric dermatology through the launch of Berrysoft Baby range under Wanbury Skin Health • Finance Cost Savings: Refinanced borrowings at lower interest rates, with reduced finance costs expected to benefit upcoming quarters • Product Pipeline: Strengthening commercialisation opportunities through development and evaluation of additional APIs

WANBURY LIMITED

← Back to feed